We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+135.58%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$88.6M
AUM Growth
+$16.2M
Cap. Flow
-$29.9M
Cap. Flow %
-33.78%
Top 10 Hldgs %
99.28%
Holding
21
New
3
Increased
7
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
AGRX
Agile Therapeutics
AGRX
+$1.04M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$278K
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$170K
4
GARS
Garrison Capital Inc.
GARS
+$155K
5
CDTX
Cidara Therapeutics
CDTX
+$72.4K

Top Sells

Rank Stock Value
1
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$1.84M
2
ACAS
American Capital Ltd
ACAS
+$1.04M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$221K
4
ABUS icon
Arbutus Biopharma
ABUS
+$173K
5
ASMB icon
Assembly Biosciences
ASMB
+$111K

Sector Composition

Rank Sector Weight
1 Healthcare 7.07%
2 Financials 2.33%
3 Industrials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPXX
1
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$67.4M 76%
2,232,272
-90,497
-4% -$1.84M
AGRX
2
DELISTED
Agile Therapeutics
AGRX
$12M 13.57%
790
+76
+11% +$1.04M
MDGL icon
3
Madrigal Pharmaceuticals
MDGL
$12.6B
$5.67M 6.39%
622,019
+1,881
+0.3% +$22.6K
BRK.B icon
4
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.29M 1.46%
8,945
-171
-2% -$24.4K
CSW
5
CSW Industrials
CSW
$4.91B
$367K 0.41%
11,253
+347
+3% +$11.3K
SCM icon
6
Stellus Capital Investment Corp
SCM
$243M
$304K 0.34%
29,728
+6,239
+27% +$63.2K
ICMB icon
7
Investcorp Credit Management BDC
ICMB
$12.4M
$295K 0.33%
33,480
+5,062
+18% +$43.5K
PRTK
8
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$263K 0.3%
+18,909
New +$278K
DOV icon
9
Dover
DOV
$29.3B
$223K 0.25%
3,991
-76
-2% -$4.1K
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$194K 0.22%
940
+299
+47% +$72.4K
PFX icon
11
PhenixFIN
PFX
$80.3M
$167K 0.19%
1,246
-109
-8% -$14.4K
ACSF
12
DELISTED
American Capital Senior Floating, Ltd.
ACSF
$157K 0.18%
15,255
-202
-1% -$2.06K
GARS
13
DELISTED
Garrison Capital Inc.
GARS
$152K 0.17%
+15,104
New +$155K
SBBP
14
DELISTED
Strongbridge Biopharma plc.
SBBP
$143K 0.16%
+35,977
New +$170K
MDGL icon
15
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$19K 0.02%
2,057
+143
+7% +$1.72K
ABUS icon
16
Arbutus Biopharma
ABUS
$936M
– –
-41,903
Closed -$173K
ASMB icon
17
Assembly Biosciences
ASMB
$512M
– –
-1,849
Closed -$111K
IWM icon
18
PUT
iShares Russell 2000 ETF
IWM
$82.2B
– –
-5,338
Closed -$591K
KPTI icon
19
Karyopharm Therapeutics
KPTI
$213M
– –
-1,655
Closed -$221K
SPY icon
20
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
– –
-135,186
Closed -$27.8M
ACAS
21
DELISTED
American Capital Ltd
ACAS
– –
-68,537
Closed -$1.04M

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2016 Portfolio in Review

As of Q2 2016, Caxton Corporation held 21 positions worth $88.6M, up 22% from $72.5M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Caxton Corporation withdrew a net $29.9M in Q2 2016, closing 6 positions and reducing 5 holdings. Its most notable exit was American Capital Ltd, an estimated $1.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.1% of assets, down from 8.1% a quarter earlier, followed by Financials and Industrials.

Against the trend, Caxton Corporation opened a new position in Paratek Pharmaceuticals, Inc. worth $263K.

  • Caxton Corporation's largest Q2 2016 buy was Paratek Pharmaceuticals, Inc.: 18,909 shares worth $263K.
  • Caxton Corporation added most to Agile Therapeutics in Q2 2016, an estimated $1.04M increase.
  • Caxton Corporation's biggest Q2 2016 reduction was CELATOR PHARMACEUTICALS INC. COMMON STOCK, cutting an estimated $1.84M.
  • Caxton Corporation fully exited American Capital Ltd in Q2 2016, selling an estimated $1.04M.
  • Caxton Corporation's ten largest holdings make up 99% of its $88.6M portfolio in Q2 2016.
  • Caxton Corporation opened 3 new positions and closed 6 in Q2 2016.
  • Caxton Corporation's portfolio value rose 22% quarter-over-quarter to $88.6M.

Based on Caxton Corporation's 13F filing for Q2 2016, filed 15 Aug 2016.